These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38573968)

  • 21. Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer.
    Wei G; An P; Vaid KA; Nasser I; Huang P; Tan L; Zhao S; Schuppan D; Popov YV
    Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G174-G188. PubMed ID: 31630534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral Administration of Mulberry (
    Wakame K; Sato K; Kasai M; Kikuchi E; Shimizu K; Kudo A; Komatsu KI; Nakata A
    Anticancer Res; 2022 Aug; 42(8):4055-4062. PubMed ID: 35896224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis.
    Hansen HH; Pors S; Andersen MW; Vyberg M; Nøhr-Meldgaard J; Nielsen MH; Oró D; Madsen MR; Lewinska M; Møllerhøj MB; Madsen AN; Feigh M
    Sci Rep; 2023 Dec; 13(1):23056. PubMed ID: 38155202
    [TBL] [Abstract][Full Text] [Related]  

  • 24. miR-21-5p promotes NASH-related hepatocarcinogenesis.
    Rodrigues PM; Afonso MB; Simão AL; Islam T; Gaspar MM; O'Rourke CJ; Lewinska M; Andersen JB; Arretxe E; Alonso C; Santos-Laso Á; Izquierdo-Sanchez L; Jimenez-Agüero R; Eizaguirre E; Bujanda L; Pareja MJ; Prip-Buus C; Banales JM; Rodrigues CMP; Castro RE
    Liver Int; 2023 Oct; 43(10):2256-2274. PubMed ID: 37534739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liver cyclophilin D deficiency inhibits the progression of early NASH by ameliorating steatosis and inflammation.
    Li X; Yang M; Sun H; Ferdous MRU; Gao L; Zhao J; Song Y
    Biochem Biophys Res Commun; 2022 Feb; 594():168-176. PubMed ID: 35085894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish.
    de Oliveira S; Houseright RA; Graves AL; Golenberg N; Korte BG; Miskolci V; Huttenlocher A
    J Hepatol; 2019 Apr; 70(4):710-721. PubMed ID: 30572006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glucagon-Like Peptide-1 Receptor Agonist Prevented the Progression of Hepatocellular Carcinoma in a Mouse Model of Nonalcoholic Steatohepatitis.
    Kojima M; Takahashi H; Kuwashiro T; Tanaka K; Mori H; Ozaki I; Kitajima Y; Matsuda Y; Ashida K; Eguchi Y; Anzai K
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32785012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential progression of unhealthy diet-induced hepatocellular carcinoma in obese and non-obese mice.
    Hymel E; Vlock E; Fisher KW; Farazi PA
    PLoS One; 2022; 17(8):e0272623. PubMed ID: 35994501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new NASH model in aged mice with rapid progression of steatohepatitis and fibrosis.
    Li X; Lu Y; Liang X; Zhou X; Li D; Zhang Z; Niu Y; Liu S; Ye L; Zhang R
    PLoS One; 2023; 18(5):e0286257. PubMed ID: 37228085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects.
    Kawakubo M; Tanaka M; Ochi K; Watanabe A; Saka-Tanaka M; Kanamori Y; Yoshioka N; Yamashita S; Goto M; Itoh M; Shirakawa I; Kanai S; Suzuki H; Sawada M; Ito A; Ishigami M; Fujishiro M; Arima H; Ogawa Y; Suganami T
    Sci Rep; 2020 Jan; 10(1):983. PubMed ID: 31969650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differences in metabolic and liver pathobiology induced by two dietary mouse models of nonalcoholic fatty liver disease.
    Zhang H; Léveillé M; Courty E; Gunes A; N Nguyen B; Estall JL
    Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E863-E876. PubMed ID: 32924526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peretinoin, an acyclic retinoid, suppresses steatohepatitis and tumorigenesis by activating autophagy in mice fed an atherogenic high-fat diet.
    Okada H; Takabatake R; Honda M; Takegoshi K; Yamashita T; Nakamura M; Shirasaki T; Sakai Y; Shimakami T; Nagata N; Takamura T; Tanaka T; Kaneko S
    Oncotarget; 2017 Jun; 8(25):39978-39993. PubMed ID: 28591717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Gene Expression Patterns Between Mouse Models of Nonalcoholic Fatty Liver Disease and Liver Tissues From Patients.
    Teufel A; Itzel T; Erhart W; Brosch M; Wang XY; Kim YO; von Schönfels W; Herrmann A; Brückner S; Stickel F; Dufour JF; Chavakis T; Hellerbrand C; Spang R; Maass T; Becker T; Schreiber S; Schafmayer C; Schuppan D; Hampe J
    Gastroenterology; 2016 Sep; 151(3):513-525.e0. PubMed ID: 27318147
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis.
    Wang X; Zeldin S; Shi H; Zhu C; Saito Y; Corey KE; Osganian SA; Remotti HE; Verna EC; Pajvani UB; Schwabe RF; Tabas I
    J Hepatol; 2022 Apr; 76(4):910-920. PubMed ID: 34902531
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Li T; Lin X; Shen B; Zhang W; Liu Y; Liu H; Wang Y; Zheng L; Zhi F
    Front Immunol; 2022; 13():1047570. PubMed ID: 36531991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Small-Molecule Inhibitors of Cyclophilins Block Opening of the Mitochondrial Permeability Transition Pore and Protect Mice From Hepatic Ischemia/Reperfusion Injury.
    Panel M; Ruiz I; Brillet R; Lafdil F; Teixeira-Clerc F; Nguyen CT; Calderaro J; Gelin M; Allemand F; Guichou JF; Ghaleh B; Ahmed-Belkacem A; Morin D; Pawlotsky JM
    Gastroenterology; 2019 Nov; 157(5):1368-1382. PubMed ID: 31336123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Establishment and evaluation of a mouse model of nonalcoholic steatohepatitis-related hepatocellular carcinoma].
    Luo Y; Yang WJ; Chen JY; Zhang J; Zeng XD; Zhuang ZJ; Zang SF; Zhou G; Di CH; Shi JP
    Zhonghua Gan Zang Bing Za Zhi; 2016 Apr; 24(4):279-84. PubMed ID: 27470627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
    Dhamija E; Paul SB; Kedia S
    Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
    Zhu C; Ho YJ; Salomao MA; Dapito DH; Bartolome A; Schwabe RF; Lee JS; Lowe SW; Pajvani UB
    J Hepatol; 2021 Mar; 74(3):613-626. PubMed ID: 33038431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.